Psilocybin's effects on anhedonia

Phase 1

• Conditions: Major Depressive Disorder; MedDRA version: 23.0Level: LLTClassification code: 10083288Term: Clinical depression Class: 10037175; MedDRA version: 24.0Level: LLTClassification code: 10056941Term: MRI brain Class: 10022891; MedDRA version: 20.0Level: PTClassification code: 10002511Term: Anhedonia Class: 100000004873; MedDRA version: 20.0Level: LLTClassification code: 10027942Term: Mood depression Class: 10037175; MedDRA version: 21.1Level: PTClassification code: 10054976Term: Antidepressant therapy Class: 100000004865; Therapeutic area: Psychiatry and Psychology [F] - Psychological Phenomena [F02]; Therapeutic area: Psychiatry and Psychology [F] - Behavior and Behavior Mechanisms [F01]; Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]

• Registration Number: CTIS2023-509009-59-00
• Lead Sponsor: Medical University of Vienna

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-04-18
• Last Update Posted: 21 August 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s):